Pathos AI 周五表示，已与百时美施贵宝和 Tempus AI 达成合作，开发用于阿尔茨海默病及其他神经系统疾病药物研发的人工智能工具。
Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.
Pathos AI 还完成了一轮 2.37 亿美元的 E 轮融资，由百时美施贵宝领投，该轮融资使这家总部位于纽约的公司估值约为 30 亿美元，现有投资者也参与了投资。以下是其他细节：Tempus 将利用数十万名神经系统疾病患者的数据构建数据集，以帮助追踪疗效并加速疾病生物学研究；Pathos 将根据一项为期五年、金额为 5500 万美元的协议，从 Tempus 处获得数据许可；Pathos 将应用其 AI 平台 Pathos Foundry 对该数据集进行大规模研究，生成并检验疾病生物学假设，并为设计更具针对性、适应性的临床试验提供依据；百时美施贵宝将获得 Pathos Foundry 在其更广泛产品组合中的非独家战略访问权，以及在其神经科学开发项目中使用该平台的为期三年的独家权利。
融资所得将用于进一步扩大 Foundry 平台的能力，并加速其 AI 驱动管线的开发，包括推进实验性抗癌药物 JSKN016。该笔资金还将有助于推进其他癌症项目的开发，包括与阿斯利康（AZN.L）合作的实验性乳腺癌药物。
Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors. Here are some other details: Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology Pathos will license the data from Tempus under a five-year, $55 million agreement Pathos will apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year exclusive rights to use the platform for its neuroscience development programs Proceeds from the financing will be used to further scale the Foundry platform's capabilities and accelerate development of its AI-driven pipeline, including advancing experimental cancer drug, JSKN016 The funding will help advance development of other cancer programs including an AstraZeneca (AZN.L)-partnered experimental breast cancer drug